CALLIDITAS THERAPEUTICS AB's ticker is CALT and the CUSIP is 13124Q106. A total of 18 filers reported holding CALLIDITAS THERAPEUTICS AB in Q3 2023. The put-call ratio across all filers is 10.22 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,695,000 | +16.3% | 750,000 | 0.0% | 0.37% | +12.5% |
| Q2 2023 | $11,775,000 | -34.4% | 750,000 | 0.0% | 0.33% | -50.1% |
| Q1 2023 | $17,962,500 | +36.6% | 750,000 | 0.0% | 0.66% | +18.4% |
| Q4 2022 | $13,147,500 | +16.1% | 750,000 | 0.0% | 0.56% | +18.6% |
| Q3 2022 | $11,325,000 | -16.0% | 750,000 | 0.0% | 0.47% | -28.1% |
| Q2 2022 | $13,478,000 | -3.0% | 750,000 | 0.0% | 0.65% | +17.1% |
| Q1 2022 | $13,898,000 | -25.2% | 750,000 | 0.0% | 0.56% | -17.5% |
| Q4 2021 | $18,570,000 | +14.5% | 750,000 | 0.0% | 0.67% | +6.5% |
| Q3 2021 | $16,215,000 | -26.6% | 750,000 | 0.0% | 0.63% | -23.6% |
| Q2 2021 | $22,080,000 | +6.5% | 750,000 | 0.0% | 0.83% | +6.6% |
| Q1 2021 | $20,723,000 | -18.7% | 750,000 | 0.0% | 0.78% | -22.5% |
| Q4 2020 | $25,493,000 | +41.6% | 750,000 | 0.0% | 1.00% | +2.3% |
| Q3 2020 | $18,000,000 | +3.0% | 750,000 | 0.0% | 0.98% | -9.0% |
| Q2 2020 | $17,475,000 | – | 750,000 | – | 1.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 200,000 | $6,724,000 | 2.33% |
| BVF INC/IL | 750,000 | $25,493,000 | 1.00% |
| Logos Global Management LP | 300,000 | $10,086,000 | 0.86% |
| Vivo Capital, LLC | 311,030 | $10,457,000 | 0.47% |
| HHLR ADVISORS, LTD. | 1,047,687 | $35,611,000 | 0.28% |
| Pentwater Capital Management LP | 50,000 | $1,681,000 | 0.02% |
| Point72 Asset Management, L.P. | 102,748 | $3,454,000 | 0.02% |
| DEUTSCHE BANK AG\ | 70,236 | $2,361,000 | 0.00% |
| MILLENNIUM MANAGEMENT LLC | 20,484 | $696,000 | 0.00% |
| JANE STREET GROUP, LLC | 7,557 | $256,000 | 0.00% |